Kristen Ciombor, MD, MSCI

Experts discuss their vision for the future of colorectal cancer treatment and anticipated advancements in the field.

The panel of leading oncologists summarize crucial updates and key insights on colorectal cancer from the ASCO 2024 conference.

Colorectal cancer specialists examine treatment sequencing strategies for third-line and subsequent therapy settings, while also evaluating regorafenib's efficacy and real-world outcomes.

Oncology experts evaluate the influence of fruquintinib on current treatment protocols, drawing insights from the FRESCO and FRESCO-2 clinical studies.

Leading colorectal cancer specialists analyze the SUNLIGHT trial results, focusing on age-related efficacy data and its implications for treatment strategies.

Key opinion leaders explore treatment selection for third-line metastatic colorectal cancer patients, examining factors influencing therapy choice with particular focus on comparing fruquintinib to TAS-102 (with or without bevacizumab).

The colorectal cancer experts offer insights on a patient case and investigate the obstacles faced by patients with metastatic colorectal cancer requiring third-line or later therapy.

The panel examines prevalent adverse events experienced by patients receiving second-line biomarker-directed therapy for metastatic colorectal cancer.

The panel examines data from the ZL-IRIAN study and Phase II study, which provide insights into second-line treatment options for patients with metastatic colorectal cancer.

Key opinion leaders outline their strategies for sequencing second-line treatments in chemotherapy-refractory metastatic colorectal cancer patients, considering the influence of previous therapies on their decision-making process.

The panel of CRC experts explores the significance of molecular testing for mCRC patients, emphasizing recommended biomarkers and optimal testing timelines.

Expert panelists identify key takeaways and share their excitement for future directions in the management of metastatic colorectal cancer.

Before closing out their review of combination therapy in metastatic colorectal cancer, panelists discuss the STELLAR-303 and SUNLIGHT clinical trials.

A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer.

A focused discussion on combination strategies with immune checkpoint inhibitors in patients with metastatic colorectal cancer.

Switching their focus to immune checkpoint inhibitors, panelists provide an overview on the role of immunotherapy in metastatic colorectal cancer.

Before closing out their discussion on BRAF-mutated metastatic colorectal cancer, panelists consider other novel combination strategies in this setting.

Shared insight on the BREAKWATER trial, which combined encorafenib, cetuximab, and chemotherapy in patients with BRAF V600E–mutated metastatic colorectal cancer.

Expert perspectives on the BEACON CRC trial, which combined encorafenib, cetuximab, and binimetinib in patients with BRAF V600E–mutated metastatic colorectal cancer.

Following its discussion on trastuzumab deruxtecan and tucatinib therapy in HER2+ mCRC, the panel emphasizes the importance HER2 status identification in metastatic colorectal cancer.

Switching their focus to tucatinib, expert panelists review data from the MOUNTAINEER study and define the role of tucatinib in managing HER2+ metastatic colorectal cancer.

Comprehensive insight on the adverse event profile of antibody drug conjugate therapy as it compares to other agents in HER2+ metastatic colorectal cancer management.

Centering discussion on clinical trials and experience with trastuzumab deruxtecan, expert oncologists identify its value in the HER2+ treatment landscape.

After a brief overview on first-line treatment options for patients with metastatic colorectal cancer, panelists highlight the role HER2 status plays in the selection of novel therapies.

A comprehensive discussion on the barriers to molecular testing in metastatic colorectal cancer, along with challenges in utilizing these tests in the real-world setting.

Panelists consider the potential role for circulating tumor DNA to inform the selection of therapy for patients with metastatic colorectal cancer.

Shared insight on the value tissue and circulating tumor DNA respectively provide in molecular testing for patients with metastatic colorectal cancer.

Experts in metastatic colorectal cancer management highlight the role of molecular testing and testing modalities available in the academic and community settings.

Kristen K. Ciombor, MD, MSCI, discusses data evaluating the utility of rechallenging with EGFR inhibitors in RAS/RAF wild-type colorectal cancer.

Kristen K. Ciombor, MD, MSCI, discusses the use of panitumumab in the maintenance treatment of patients with RAS wild-type metastatic colorectal cancer.